The expression and function of RASAL2 in renal cell carcinoma angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Renal cell carcinoma (RCC) frequently develops resistance to anti-vascular therapies.
• The molecular mechanisms driving this resistance and tumor progression are not fully understood.
• Identifying novel therapeutic targets is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the role of RASAL2 (RAS GTPase-activating protein) in renal cell carcinoma.
• To elucidate the molecular mechanisms by which RASAL2 affects tumor angiogenesis and drug resistance.
• To explore the potential of targeting the RASAL2 pathway for RCC treatment.

Main Methods:

• Analysis of RASAL2 epigenetic silencing in RCC patient samples.
• In vitro and in vivo studies to assess the effect of RASAL2 on angiogenesis.
• Investigation of the molecular pathway involving RASAL2, GSK3β, c-FOS, and VEGFA.
• Utilizing specific inhibitors and small interfering RNA (siRNA) to modulate pathway components.

Main Results:

• RASAL2 is frequently epigenetically silenced in RCC, and its loss correlates with reduced patient survival.
• RASAL2 demonstrates significant inhibition of RCC angiogenesis both in vitro and in vivo.
• RASAL2 activates GSK3β (glycogen synthase kinase 3 beta) by reducing Ser9 phosphorylation.
• This activation leads to decreased expression of c-FOS and vascular endothelial growth factor A (VEGFA).

Conclusions:

• RASAL2 functions as a tumor suppressor in renal cell carcinoma by targeting angiogenesis.
• The RASAL2/p-GSK3β/c-FOS/VEGFA pathway is a key regulator of RCC angiogenesis.
• Targeting this pathway offers a potential strategy to overcome resistance to anti-vascular therapies in RCC.